Assessing three day pentamidine for early stage human African trypanosomiasis (Angola)
ISRCTN | ISRCTN35617647 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN35617647 |
Secondary identifying numbers | A30765 |
- Submission date
- 15/04/2005
- Registration date
- 07/06/2005
- Last edited
- 06/12/2007
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Melba Gomes
Scientific
Scientific
20, Avenue Appia
Geneva -27
CH 1211
Switzerland
gomesm@who.int |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Scientific title | |
Study objectives | Pharmacokinetic studies have shown that pentamidine has a large volume of distribution and elimination occurs over a long period. The objective of the study is to assess the efficacy of 3 days Intramuscular (IM) pentamidine treatment compared to the standard 7 days IM pentamidine treatment regimen. |
Ethics approval(s) | Ethics approval received from: 1. World Health Organization (WHO)/Ethics Review Committee (ERC) on the 4th December 2003 2. Instituto de Combate e Control o Das Triponosommiases (ICCT) (Angola) on the 18th October 2004 3. Wandsworth Local Research Ethics Committee (UK) on the 3rd December 2003 |
Health condition(s) or problem(s) studied | Human African Trypanosomiasis (HAT) |
Intervention | This will be an open, randomised comparison of two pentamidine treatment regimens, given over three days or seven days with a non-inferiority trial design. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Pentamidine |
Primary outcome measure | Proportion of cases with favourable progress at 6 months, based on clinical state and laboratory status. |
Secondary outcome measures | 1. Proportion of cases with favourable progress at discharge, 3 and 12 months based on clinical state and laboratory status 2. Cure rate at 18 months, based on based on clinical state and laboratory status 3. Frequency and severity of adverse events |
Overall study start date | 20/12/2004 |
Completion date | 20/12/2006 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | The total target was 440 patients, but only 18 were recruited in this site. |
Key inclusion criteria | 1. Aged more than or equal to 14 years and less than 60 years 2. Parasite positive (on examination of lymph juice, by Capillary Tube Centrifugation [CTC] or miniature Anion-Exchange Centrifugation [mAEC] on whole blood) 3. Alternative diagnoses excluded clinically and by appropriate laboratory investigations 4. Capable of and giving informed consent to the study |
Key exclusion criteria | 1. Stage II Human African Trypanosomiasis (HAT): defined as parasites in cerebrospinal fluid (CSF), or having more than or equal to 6 cells/mm^3 in CSF; or more than 100 red cells/mm^3 ("bloody tap") 2. Pregnant 3. Previous HAT 4. Known allergy or reactions to pentamidine 5. Diabetes mellitus 6. Difficulty to comply with follow-up (patients of no fixed abode and refugees, for example) |
Date of first enrolment | 20/12/2004 |
Date of final enrolment | 20/12/2006 |
Locations
Countries of recruitment
- Angola
- Switzerland
Study participating centre
20, Avenue Appia
Geneva -27
CH 1211
Switzerland
CH 1211
Switzerland
Sponsor information
UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)
Other
Other
20, Avenue Appia
Geneva -27
CH 1211
Switzerland
Website | http://www.who.int |
---|---|
https://ror.org/01f80g185 |
Funders
Funder type
Research organisation
United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |